Pancreatic Cancer Research

ResearcherLawrence Berkeley National LaboratoryActive in the last 2 years

Anguraj Sadanandam

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-8485-5150; OpenAlex author ID A5053519097. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
83
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 2 papers · 2023: 2 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 12

  1. Coordinated immune architecture underlies durable survival in pancreatic cancer Co-author DOI 10.64898/2026.04.29.721612↗
  2. SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer. Co-author DOI 10.1038/s41586-025-09574-y↗
  3. The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities. Last author DOI 10.1002/path.6171↗
  4. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Co-author DOI 10.1038/s41586-023-06073-w↗
  5. GREM1 is required to maintain cellular heterogeneity in pancreatic cancer. Co-author DOI 10.1038/s41586-022-04888-7↗
  6. A Case Report on Longitudinal Collection of Tumour Biopsies for Gene Expression-Based Tumour Microenvironment Analysis from Pancreatic Cancer Patients Treated … Co-author DOI 10.3390/curroncol29100531↗
  7. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Co-author DOI 10.1038/s41467-021-27099-6↗
  8. Nutrient profiling reveals extracellular uridine as a fuel for pancreatic cancer through uridine phosphorylase 1 Co-author DOI 10.1101/2021.06.07.447448↗
  9. Immunological combination treatment holds the key to improving survival in pancreatic cancer. Co-author DOI 10.1007/s00432-020-03332-5↗
  10. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/path.5224↗
  11. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer. Co-author DOI 10.1016/j.cell.2014.06.003↗
  12. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. First author DOI 10.1038/nm.2344↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jessica Kristine Nelson · 2 shared papers, 2022–2025 · strength 0.31
  2. Linxiang Lan · 2 shared papers, 2022–2025 · strength 0.31
  3. Huafu Li · 2 shared papers, 2022–2025 · strength 0.31
  4. Axel Behrens · 2 shared papers, 2022–2025 · strength 0.31
  5. Melanie Herpels · 1 shared paper, 2023 · strength 0.31
  6. Mikael Hans Sodergren · 2 shared papers, 2020–2022 · strength 0.29
  7. Nagina Mangal · 2 shared papers, 2020–2022 · strength 0.29
  8. Nagy Adley Habib · 2 shared papers, 2020–2022 · strength 0.29
  9. Hemant Mahendrakumar Kocher · 2 shared papers, 2019–2022 · strength 0.24
  10. Christopher J. Halbrook · 2 shared papers, 2021–2023 · strength 0.24
  11. Rosa Elena Menjivar · 2 shared papers, 2021–2023 · strength 0.24
  12. Zeribe C. Nwosu · 2 shared papers, 2021–2023 · strength 0.24
  13. Eileen S. Carpenter · 2 shared papers, 2021–2023 · strength 0.24
  14. Matthew H. Ward · 2 shared papers, 2021–2023 · strength 0.24
  15. Marina Pasca di Magliano · 2 shared papers, 2021–2023 · strength 0.24
  16. Li Zhang · 2 shared papers, 2021–2023 · strength 0.24
  17. Costas Andreas Lyssiotis · 2 shared papers, 2021–2023 · strength 0.24
  18. Nabeel Merali · 1 shared paper, 2026 · strength 0.21
  19. Nicola E. Annels · 1 shared paper, 2026 · strength 0.21
  20. Rachael J. M. Bashford-Rogers · 1 shared paper, 2026 · strength 0.21
  21. Tarak Agrebi Moumni Chouari · 1 shared paper, 2026 · strength 0.21
  22. Michael Loran Dustin · 1 shared paper, 2026 · strength 0.21
  23. Shihong Wu · 1 shared paper, 2026 · strength 0.21
  24. Elisa Giovannetti · 1 shared paper, 2026 · strength 0.21
  25. Adam Enver Frampton · 1 shared paper, 2026 · strength 0.21

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.